<DOC>
	<DOCNO>NCT00430092</DOCNO>
	<brief_summary>The purpose phase III study determine efficacy difluprednate treatment inflammation follow ocular surgery .</brief_summary>
	<brief_title>Study Difluprednate Treatment Inflammation Following Ocular Surgery ( ST-601A-002b )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Unilateral ocular surgery day prior study enrollment . Anterior chamber cell grade ≥ `` 2 '' day surgery ( Day 1 ) . Aged 2 year old day consent . Negative urine pregnancy test Day 1 postmenarchal subject ; negative urine pregnancy test premenarchal subject investigator 's discretion . Provide sign write consent prior enter study sign write consent parent legal guardian subject minor sign assent minor subject , appropriate . Presurgical Systemic administration corticosteroid 2 week prior study enrollment . Periocular injection study eye corticosteroid solution within 4 week prior instillation study drug , corticosteroid depot within 2 month prior instillation study drug . Instillation topical ocular corticosteroid NSAID within 24 hour prior instillation study drug course study , exception presurgical administration topical NSAID prevent miosis . Any history glaucoma ocular hypertension study eye . History presence endogenous uveitis . Any current corneal abrasion ulceration . Any confirm suspect active viral , bacterial , fungal keratoconjunctival disease . Allergy similar drug , corticosteroid . History steroidrelated IOP increase . Scheduled surgery contralateral eye treatment period . Unwilling discontinue use contact lenses study period . Pregnancy lactation . Participation study investigational topical systemic new drug device within 30 day prior screen , time study . Prior participation study describe protocol . Unable unwilling give sign informed consent prior participation study related procedure . Postsurgical Ocular hemorrhage interfere evaluation postsurgery inflammation . Injection gas vitreous body surgery . Presence IOP ≥24 mm Hg Day 1 surgery .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>